Can Wegovy Affect Your Eyesight? What the Clinical Evidence Shows

Where the concern first appeared: the SUSTAIN-6 trial finding

The retinopathy signal emerged from SUSTAIN-6, a cardiovascular safety trial in adults with type 2 diabetes, not from the STEP weight-management programme. In SUSTAIN-6, diabetic retinopathy complications occurred in 3.0% of the semaglutide group versus 1.8% on placebo, a statistically significant difference that prompted regulators to add a warning to the prescribing information. The leading hypothesis is that rapid, early falls in HbA1c triggered or accelerated existing retinal changes, mirroring a phenomenon long observed when intensive insulin therapy is started quickly in people with poorly controlled diabetes.

The STEP trials, which form the evidence base for Wegovy's weight-management licence, enrolled adults without diabetes. Clinically significant retinopathy complications were not a notable finding in that programme. That distinction matters: the populations, the baseline eye health, and the metabolic starting points were different. You can read the NHS patient information for semaglutide, which covers this context clearly, at the NHS semaglutide medicines page.

This is a question our prescribers hear most weeks, often from people who have read about the SUSTAIN-6 result without the context that it came from a diabetes trial. The short answer is that the risk profile looks different depending on whether you have diabetes and, if so, how well controlled it is.

NAION: a rarer concern that attracted regulatory attention

Non-arteritic anterior ischaemic optic neuropathy (NAION) is a sudden reduction in blood supply to the optic nerve, causing painless vision loss, usually in one eye. It is rare in the general population. A 2024 observational study published in JAMA Ophthalmology found a statistically elevated rate of NAION among people taking semaglutide compared to those on other weight-loss treatments or diabetes medicines. The study was observational, so it cannot prove causation, and absolute numbers remained small.

The MHRA and the European Medicines Agency both reviewed the data. As of the time of writing, the MHRA has not concluded that semaglutide causes NAION; the signal is under continued monitoring. Novo Nordisk's prescribing information was updated to note NAION as a condition that has been reported. For practical purposes: if you develop sudden painless vision loss or significant change in one eye while on any semaglutide-containing medicine, it is a medical emergency regardless of what is causing it. Do not wait for a routine appointment. This applies to semaglutide in all its licensed forms, not only the weight-management injection.

The MHRA's Yellow Card scheme allows patients and healthcare professionals to report suspected side effects; the link is yellowcard.mhra.gov.uk.

What this means for people considering Wegovy for weight management

For adults starting Wegovy without diabetes, the retinopathy signal from SUSTAIN-6 is less directly relevant. Good prescribing practice still involves a thorough medical history, and anyone with a pre-existing retinal condition should discuss it explicitly with their prescriber before starting. The same principle applies to other eye conditions that have been raised in the context of semaglutide.

The broader side-effect profile of Wegovy is dominated by gastrointestinal effects (nausea, loose stools, reflux and similar) which tend to be most noticeable in the early weeks of treatment. Vision-related effects are not common, but they are not negligible for certain patient groups, and our dedicated page on Wegovy and eyesight brings together the evidence for anyone who wants a fuller picture. The NHS medicines information for semaglutide lists the reported side effects and the circumstances under which urgent help is needed.

If you are weighing up treatment options more broadly (including how does Wegovy affect eyesight compared to other factors in your health picture) the Wegovy overview covers the full clinical context. And for anyone concerned about how nutritional changes during treatment might affect general wellbeing, the evidence on electrolytes and Wegovy is worth reading alongside the eye-health discussion.

When to get medical help

Wegovy's patient information leaflet lists the following as reasons to seek urgent care regarding your eyes: sudden deterioration of vision, or any new visual disturbance. More generally, if you experience severe or persistent abdominal pain that radiates to your back, signs of a serious allergic reaction, or symptoms of gallbladder disease while on semaglutide, those also warrant same-day medical attention rather than waiting.

For routine questions about how your individual history interacts with treatment, a prescriber is the right person to ask. The detailed evidence on semaglutide's effects on the eyes covers additional clinical detail for those wanting to go further. If you are at the stage of considering whether Wegovy is appropriate for your situation, a clinical consultation is the starting point, a prescriber can review your full medical history, including any eye conditions, before any prescription is issued. You can check your eligibility with a free consultation at any point.